Assessment of immune response in ICU admitted SARS-CoV-2 patients from Kashmir, North India

Farooq, Iqra; Eachkoti, Rafiqa; Hussain, Saleem; Haq, Inaamul; Tanvir, Masood; Amin, Shajrul; Farooq, Sanah; Saleem, Sadaf; Majid, Sabhiya

doi:10.61186/rabms.11.1.1

Volume 11, Issue 1 (1-2025) Journal of Research in Applied and Basic Medical Sciences 2025, 11(1): 1-10 | Back to browse issues page

‎ 10.61186/rabms.11.1.1

Mendeley

Zotero

RefWorks

Farooq I, Eachkoti R, Hussain S, Haq I, Tanvir M, Amin S, et al . Assessment of immune response in ICU admitted SARS-CoV-2 patients from Kashmir, North India. Journal of Research in Applied and Basic Medical Sciences 2025; 11 (1) :1-10
URL: http://ijrabms.umsu.ac.ir/article-1-335-en.html

Assessment of immune response in ICU admitted SARS-CoV-2 patients from Kashmir, North India

Iqra Farooq

, Rafiqa Eachkoti ^*

Department of Biochemistry, Government Medical College Srinagar, J&K India , rafihaq@gmail.com

Abstract: (537 Views)

Background & Aims: The present study aimed to investigate the lymphocyte subpopulation counts (Th, Tc, B-cell, and NK cell) in SARS-CoV-2 patients (admitted to the ICU) to gain greater insight into the dysregulated immune response found in COVID-19.
Materials & Methods: A total of 30 SARS-CoV-2 patients recruited in the intensive care unit (ICU) of Chest Disease (CD) and DRDO hospitals in Srinagar were investigated for lymphocyte subpopulation counts (T cell, B cell, and NK cell) by FACS analysis of blood samples (using the Beckman Coulter (Navios) and FACS Diva software).
Results: Correlation analysis of lymphocyte subpopulation counts revealed, in comparison to normal healthy controls, an overall decreased mean T cell subset count, i.e., T-helper (CD3+, CD4+) (1422.5 cell/ul vs 662.4 cell/ul); T-cytotoxic (CD3+CD8+) (973.7 cell/ul Vs 629.2 cell/ul) and B cell count (CD45+CD19+) (442.1 cell/ul Vs. 144.4 cell/ul) with CD4+/CD8+ ratio (1.4 Vs. 1) in SARS-CoV-2 patients. On comparison, Stage 3 Vs Stage 2 patients, the mean T cytotoxic lymphocyte count i.e. CD3+CD8+, was lower (518.9 cells/ul Vs. 849.9 cell/ul) and the T-helper cell count, i.e. CD3+CD4+, was higher (764.9 cell/ul Vs. 457.3 cell/ul) with CD4+/CD8+ = 1.4 Vs. 0.5. Furthermore, the antibody immune response reflected by B-cell count was lower (i.e., CD19+131.9 cell/ul) in Stage 3 patients compared to Stage 2 patients (i.e., CD19+=162.9 cell/ul). ROC analysis with disease outcome revealed raised CD3+CD4+ count (T-helper cell response: AUC = 0.70) and decreased CD19+ count (humoral immune response: AUC = 0.80) and increased NLR (AUC = 0.65) as predictors of poor disease outcome.
Conclusion: In conclusion, the study identified increased NLR, T-cell activation (increased T-helper cells), T-cytotoxic exhaustion (decreased T cytotoxic cells), and decreased humoral immune response (decreased CD19+ B cells) as predictive markers of severity and poor disease outcome in ICU-admitted patients with SARS-CoV-2.

Keywords: COVID-19, Cytokines, Kashmir, SARS-CoV-2

Full-Text [PDF 637 kb] (180 Downloads)

Type of Study: orginal article | Subject: Other

References

1. Saksena S, Chattopadhyay P. Illuminating the Immunopathology of SARS-CoV-2. Cytometry Part B .Clin Cytometry 2021;100 (1) :33-41. [DOI:10.1002/cyto.b.21988] [PMID]

2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y. Dysregulation of immune response in patients with coronavirus 2019(COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-8. [DOI:10.1093/cid/ciaa248] [PMID] [PMCID]

3. Urra JM, Cabrera CM, Porras L, R_odenas I. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol 2020;217:108486. [DOI:10.1016/j.clim.2020.108486] [PMID] [PMCID]

4. Sharif F, Khan S, Junaid A, Jahangir S, Saeed M, Ijaz M, et al. Early hematological indicators of severe COVID-19 disease in hospitalized patients: data from a South Asian population. IntJ Lab Hematol 2021;43(5):1237-42. [DOI:10.1111/ijlh.13533] [PMID] [PMCID]

5. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C. Neutrophil-tolymphocyteratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18(1):206. [DOI:10.1186/s12967-020-02374-0] [PMID] [PMCID]

6. Ma A, Cheng J, Yang J, Dong M, Liao X, Kang Y. Neutrophil-tolymphocyteratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit CareBioMed Central 2020;24:288. [DOI:10.1186/s13054-020-03007-0] [PMID] [PMCID]

7. Gao M, Liu Y, Guo M, Wang Q, Wang Y, Fan J. RegulatoryCD4+ and CD8+ T cells are negatively correlated with CD4+/CD8+ T cell ratios in patients acutely infected with SARSCoV-2. J Leukoc Biol 2020;109:91-7. [DOI:10.1002/JLB.5COVA0720-421RR] [PMID] [PMCID]

8. Liu R, Wang Y, Li J, Han H, Xia Z, Liu F. Decreased T cellpopulations contribute to the increased severity of COVID-19.Clin Chim Acta 2020;508:110-4. [DOI:10.1016/j.cca.2020.05.019] [PMID] [PMCID]

9. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID‐19 ‐ A systematic review. Life Sci 2020;254:117788. [DOI:10.1016/j.lfs.2020.117788] [PMID] [PMCID]

10. Nascimento MLF. A multivariate analysis on spatiotemporal evolution of COVID-19 in Brazil. Infect Dis Model 2020; 5: 670‐680. [DOI:10.1016/j.idm.2020.08.012] [PMID] [PMCID]

11. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. "Coronavirus Pandemic (COVID-19 OWID 2020. [Google Scholar]

12. Kuper H, Adami H-O, Trichopoulos D. Infections as a major preventable cause of human cancer. J. Intern. Med 2001;249(S741):61-74. [DOI:10.1046/j.1365-2796.2001.00742.x]

13. Kim S-L, Lee S-T, Trang KTT, Kim SH, Kim IH, Lee SO, et al. Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer. Int. J. Mol. Med 2014;33(5):1261-7. [DOI:10.3892/ijmm.2014.1669] [PMID]

14. Chen L, Flies DB. Erratum: Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol 2013;13(7):542-542. [DOI:10.1038/nri3484]

15. Lanier OL, Pérez-Herrero E, Andrea A, Bahrami K, Lee E, Ward DM, et al. A. Immunotherapy Approaches for Hematological Cancers. iScience 2022;25(11). [DOI:10.1016/j.isci.2022.105326] [PMID] [PMCID]

16. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated Exhaustion Levelsand Reduced Functional Diversity of T Cells in Peripheral Blood May Predict Severe Progression in COVID-19 Patients. Cell Mol.Immunol 2020;17(5):541-3. [DOI:10.1038/s41423-020-0401-3] [PMID] [PMCID]

17. Vivarelli S, Torino F, Scandurra F, Russo G, Bordonaro G, Pappalardo R, et al. Immune-Checkpoint Inhibitors from Cancer to COVID-19: A Promising Avenue for the Treatment of Patients with COVID-19(Review). Int.JOncol 2020;58(2):145-7. [DOI:10.3892/ijo.2020.5159] [PMID] [PMCID]

18. Toor SM, Saleh R, Sasidharan Nair V,Taha RZ, Elkord E. T-cell Responses and Therapies against SARS-CoV-2 Infection. Immunology 2020; 162(1):30-43. [DOI:10.1111/imm.13262] [PMID] [PMCID]

19. Maurice NJ, Taber AK, Prlic M. The Ugly Duckling Turned to Swan: A Change in Perception of Bystander-Activated MemoryCD8 T Cells. J Immunol 2021;206:455-62. [DOI:10.4049/jimmunol.2000937] [PMID] [PMCID]

20. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019(COVID19). Front Immunol 2020;11:827. [DOI:10.3389/fimmu.2020.00827] [PMID] [PMCID]